Ashour May, Armanious Sylvia, Rashad Heba, Gamal Heba, Shalaby Mohamad, Selim Marwa, Zaghloul Somaya, Khorshed Eman, Abdelfatah Dalia, Abdelazim Yasser
Radiation Oncology, National Cancer Institute, Cairo, EGY.
Surgical Oncology, National Cancer Institute, Cairo, EGY.
Cureus. 2024 Sep 29;16(9):e70432. doi: 10.7759/cureus.70432. eCollection 2024 Sep.
Background Watchful waiting and non-operative management of patients with complete clinical response to neoadjuvant treatment in locally advanced rectal cancers is an emerging practice now, especially in patients whose surgery would require permanent stoma. Methodology This is a retrospective study of patients presenting to the National Cancer Institute, Cairo University, Egypt from January 2005 to December 2019 with pathologically proven locally advanced rectal cancer who had a complete clinical response after neoadjuvant treatment. Patients who underwent surgery after achieving complete clinical response and patients who were kept under watchful waiting were compared in terms of overall survival (OS), disease-free survival (DFS), metastasis-free survival (MFS), and local recurrence-free survival (LRFS). Results Of the 51 patients identified, 31 (61%) went to surgery, and 20 (39%) were kept under watchful waiting. There was no difference in five-year OS between both groups (65% for both, p = 0.57). Five-year DFS for the watchful waiting group was 68% versus 62% for the surgery group (p = 0.75). Five-year LRFS was 100% in the watchful waiting group versus 83% in the surgery group (p = 0.15). Conclusions Watchful waiting after a complete clinical response to neoadjuvant treatment in locally advanced rectal cancer is feasible without compromising disease-related outcomes, especially in patients with distal rectal cancers requiring permanent stoma after surgery. However, further prospective validation is needed.
背景 对于局部晚期直肠癌患者,若对新辅助治疗有完全临床反应,采用观察等待和非手术治疗是一种新兴的做法,尤其是对于那些手术需要永久性造口的患者。方法 这是一项回顾性研究,研究对象为2005年1月至2019年12月在埃及开罗大学国家癌症研究所就诊的经病理证实为局部晚期直肠癌且新辅助治疗后有完全临床反应的患者。比较了达到完全临床反应后接受手术的患者和接受观察等待的患者的总生存期(OS)、无病生存期(DFS)、无转移生存期(MFS)和无局部复发生存期(LRFS)。结果 在确定的51例患者中,31例(61%)接受了手术,20例(39%)接受观察等待。两组的五年总生存期无差异(均为65%,p = 0.57)。观察等待组的五年无病生存期为68%,手术组为62%(p = 0.75)。观察等待组的五年无局部复发生存期为100%,手术组为83%(p = 0.15)。结论 局部晚期直肠癌新辅助治疗后完全临床反应后进行观察等待是可行的,且不影响疾病相关结局,尤其是对于术后需要永久性造口的低位直肠癌患者。然而,需要进一步的前瞻性验证。